Table 3.
Median (95%CrI) rankings (1 = best) for AUC and Emax treatment effects for Emax model 4. Simplifying assumptions on ET50 that constrain it to be equal across all treatments mean that the rankings for AUC are identical to the rankings for Emax treatment effects
| Treatment | Median AUC Rank (95% CrI) | Median Emax Rank (95% CrI) |
|---|---|---|
| Etoricoxib 60 mg/d | 1 (1, 3) | 1 (1, 3) |
| Etoricoxib 90 mg/d | 2 (1, 4) | 2 (1, 4) |
| Rofecoxib 125 mg/d | 3 (1, 6) | 3 (1, 6) |
| Etoricoxib 30 mg/d | 4 (3, 12) | 4 (3, 12) |
| Oxycodone 44 mg/d | 5 (1, 25) | 5 (1, 25) |
| Rofecoxib 25 mg/d | 6 (4, 15) | 6 (4, 15) |
| Naproxcinod 1500 mg/d | 7 (5, 11) | 7 (5, 11) |
| Naproxen 1000 mg/d | 10 (6, 14) | 10 (6, 14) |
| Celebrex 400 mg/d | 11 (6, 21) | 11 (6, 21) |
| Etoricoxib 10 mg/d | 12 (5, 27) | 12 (5, 27) |
| Naproxcinod 750 mg/d | 13 (7, 23) | 13 (7, 23) |
| Etoricoxib 5 mg/d | 14 (5, 28) | 14 (5, 28) |
| Lumiracoxib ( not reported) | 14 (7, 24) | 14 (7, 24) |
| Valdecoxib 20 mg/d | 15 (6, 25) | 15 (6, 25) |
| Rofecoxib 12 mg/d | 16 (7, 25) | 16 (7, 25) |
| Lumiracoxib 100 mg/d | 17 (11, 23) | 17 (11, 23) |
| Lumiracoxib 400 mg/d | 17 (10, 24) | 17 (10, 24) |
| Tramadol 300 mg/d | 17 (8, 24) | 17 (8, 24) |
| Valdecoxib 10 mg/d | 17 (7, 26) | 17 (7, 26) |
| Celebrex 200 mg/d | 18 (13, 23) | 18 (13, 23) |
| Lumiracoxib 200 mg/d | 19 (12, 24) | 19 (12, 24) |
| Valdecoxib 5 mg/d | 19 (8, 26) | 19 (8, 26) |
| Tramadol 400 mg/d | 20 (8, 27) | 20 (8, 27) |
| Duloxetine 90 mg/d | 22 (8, 28) | 22 (8, 28) |
| Celebrex 100 mg/d | 25 (17, 27) | 25 (17, 27) |
| Tramadol 200 mg/d | 25 (17, 27) | 25 (17, 27) |
| Tramadol 100 mg/d | 27 (22, 28) | 27 (22, 28) |
| Placebo 0 mg/d | 28 (27, 29) | 28 (27, 29) |
| Naproxcinod 250 mg/d | 29 (26, 29) | 29 (26, 29) |